• Contact us
  • Advertise with us
  • Login
Tashi Pharma
  • Home
  • Indian Pharma News
  • Global Pharma News
  • Guideline News
    • All
    • EDQM
    • EMA
    • European Commision
    • Health Canada
    • Medsafe
    • MHRA
    • SAHPRA
    • US FDA
    FDA Clinical Trial Guidances for Advancing Development of Cancer Treatments

    FDA publishes Clinical Trial Guidances for Advancing Development of Cancer Treatments

    Initiation of Voluntary Recalls Under 21 CFR Part 7, Subpart C

    US FDA publishes guidance on Initiation of Voluntary Recalls

    EMA publishes Q & A for Bootstrap methodology for f2 similarity factor

    EMA publishes Q & A on Bootstrap methodology for f2 similarity factor

    US FDA publishes product-specific guidances to facilitate generic drug development

    US FDA publishes product-specific guidances to facilitate generic drug development

    Clinical Trials Regulation comes into effect in the EU

    New Clinical Trials Regulation comes into effect in the EU

    Reflection paper Forecasting demand for medicinal products in the EU_EEA

    EMA publishes reflection paper on forecasting demand for medicinal products in the EU/EEA

    Trending Tags

    • Pharma
    • EMA
    • MHRA
    • TGA
    • US FDA
  • Articles
  • Interview
  • Company Focus
  • Pharma Jobs
    • Quality
    • Regulatory Affairs
    • Production
    • Sales and Marketing
    • Clinical
    • bioanalytical
  • Webinar
No Result
View All Result
  • Home
  • Indian Pharma News
  • Global Pharma News
  • Guideline News
    • All
    • EDQM
    • EMA
    • European Commision
    • Health Canada
    • Medsafe
    • MHRA
    • SAHPRA
    • US FDA
    FDA Clinical Trial Guidances for Advancing Development of Cancer Treatments

    FDA publishes Clinical Trial Guidances for Advancing Development of Cancer Treatments

    Initiation of Voluntary Recalls Under 21 CFR Part 7, Subpart C

    US FDA publishes guidance on Initiation of Voluntary Recalls

    EMA publishes Q & A for Bootstrap methodology for f2 similarity factor

    EMA publishes Q & A on Bootstrap methodology for f2 similarity factor

    US FDA publishes product-specific guidances to facilitate generic drug development

    US FDA publishes product-specific guidances to facilitate generic drug development

    Clinical Trials Regulation comes into effect in the EU

    New Clinical Trials Regulation comes into effect in the EU

    Reflection paper Forecasting demand for medicinal products in the EU_EEA

    EMA publishes reflection paper on forecasting demand for medicinal products in the EU/EEA

    Trending Tags

    • Pharma
    • EMA
    • MHRA
    • TGA
    • US FDA
  • Articles
  • Interview
  • Company Focus
  • Pharma Jobs
    • Quality
    • Regulatory Affairs
    • Production
    • Sales and Marketing
    • Clinical
    • bioanalytical
  • Webinar
No Result
View All Result
No Result
View All Result
Home Articles

MOST INNOVATIVE BIOTECH STARTUPS TO LOOK FORWARD IN 2021

By Anjali Gajra

PRN by PRN
May 25, 2021
in Articles
652 6
0
MOST INNOVATIVE BIOTECH STARTUPS TO LOOK FORWARD TO IN 2021

Biotechnology

425
SHARES
1k
VIEWS

India is one of the top 12 destinations for biotechnology around the world. Right now, India biotechnology industry makes up only 3% of the by and large worldwide biotech market ($11.1 billion/₹81,680 crore) yet this number is relied upon to go up to 19% by 2025 ($100 billion/₹7.5lakh crore) that is very nearly one-fifth of the world’s biotech area. Indian Biotech industry has grown more than 4 times from 2017 to 2018 ($11.1B to $51B) The biotechnology business in India includes >2700 biotech new companies and is assessed to reach 10,000 by 2024 which expects to give excellent medications, better analysis and MedTech items accessible at sensible cost.

Let’s look at the top Most Innovative Biotech Startups to look forward to this year:

5. BUGWORKS RESEARCH INDIA PVT LTD:

  • Founder Anand Anandkumar, lost his father who was a physician to an infection in Chennai. In and out of the hospital for a failing heart, he picked up a bug resistant to most antibiotics and died of complications from sepsis. The story is a common one in India, where so-called superbugs kill nearly 60,000 newborn every year. The rapid spread of resistant bacteria has now made India the epicenter of a war to prevent a post-antibiotic world, where people would once again die in their thousands of commonplace infections.

    Bugworks Research India Pvt. Ltd.
    Bugworks
  • We’re on the front line,” said Anandkumar, who co-founded Bengaluru-based startup Bugworks Research India Pvt Ltd a year after his father’s death, to develop new antibiotics. “We’re creating a bullet against organisms that are taking out humanity. Wouldn’t it be nice to get a battleground to test it on that’s really tough?” A study of one hospital in South India found half the patients acquired at least one infection during their stay, with about 74 percent of those infections showing resistance to multiple drugs.
  • Last year, Bugworks became the first company in Asia to receive investment from CARB-X, the US government’s main funding vehicle for the fight against superbugs.
  • Bugworks’ answer is an antibiotic that attacks bacteria in two ways at once rather than the single target approach of traditional drugs, making it harder for the bug to develop resistance. The drug also evades the bacteria’s own defenses, giving it more time to kill the infection. Anandkumar says the compound has shown effectiveness against lung, blood and urinary tract infections in animals. In about two years he says it should be ready for human trials.
  • One thing that drives the effort in India is the personal experience of so many researchers. Staff at Bugworks recount stories of friends in their forties dying in hospital from pneumonia, or from a urinary tract infection that lasts months as one antibiotic after another fails to work.
  • The biopharma startup has raised $16.5M from University of Tokyo Edge Capital, Global Brain Corporation & Aquipharma Holdings.

4. ZUMUTOR BIOLOGICS:

  • In the early 2015, Kavita Iyer Rodrigues’s company ‘Theramyt’, as it was known then had seen two rounds of funding totaling $12 million. It had become one of the 10 companies that enable new molecule development focusing on cancer.

    Zumutor Biologics
    Zumutor Biologics
  • In mid-2015, the founders decided to move to the U.S, Theramyt became Zumutor, headquartered in Boston, a biotech hub. This was to raise funds and gain market access; R&D however would continue out of the Bengaluru office.
  • “Our first-in class lead molecule, ZM 008 has made industry validated progress and is poised for IND filing with Phase 1a/1b clinical trials likely to commence end of 2020”, said Kavita Iyer Rodrigues.
  • The startup was one of the finalists in ‘The Economic Times Startup Awards’, 2019 edition.

3. VYOME THERAPEUTICS:

  • A biopharmaceutical company focused on developing dermatology products, was founded in 2010 by Shiladitya Sengupta and Venkateswarlu Nelabhotla. It develops new technologies and a pipeline of drugs for antibiotic resistant acne, other opportunistic pathogens and anti-fungal agents in dermatology using its innovative next generation therapeutics solutions.

    VYOME THERAPEUTICS
    VYOME THERAPEUTICS
  • The company has raised $48.3M from Iron Pillar, Sabre partners and Aarin Capital.
  • The company’s lead drug candidate VB 1953, is a topical treatment product candidate for antibiotic- resistant acne being studied in Phase 2 trials.
  • It has a deep pipeline of preclinical new entities, which are in unique in their ability to overcome the development of resistance and are based on its patented dual action rational therapeutics (DARTS) technology.

 2. FARCAST BIOSCIENCES:

  • Founded by Pradip. K Majumder & Mallikarjun Sundaram in 2010, Farcast Biosciences was formerly known as Mitra Biotech. It has raised $76M from Northpond Ventures, Tata Capital & Accel.
  • Boston & Bengaluru based former Mitra Biotech develops and provides novel technologies that personalize Cancer

    FARCAST BIOSCIENCES
    FARCAST BIOSCIENCES
  • At present, there’s no scientific basis for a doctor to choose a drug for a cancer. “As a population, every approved drug works, but as an individual, you don’t know which will work”, he says. A drug that works for 30% of patients, may seem great but is devastating for the rest 70%.
  • Their platform CANscript enables physicians to select most optimal drug combinations by testing a tumor sample against various drug combinations simultaneously in a laboratory setting that mimics the actual human tumor microenvironment.
  • For the patient, the test avoids toxicity from non-optimal drugs and is also a cost-saving step.
  • Their hospital clients include cancer care hospitals such as Healthcare Global (HCG) Group of Hospitals, Apollo Hospital-Delhi and Fortis Hospital-Delhi.

1. MEDGENOME:

  • Founded by Sam Santosh in 2013, it is a biotech startup that offers genome-based diagnostics and research solutions. MedGenome has raised, $119M from investors like LeapFrog Investments, Sequoia Capital and Zodius Capital.

    MEDGENOME
    MEDGENOME
  • According to MedGenome, the Indian Genetic diagnostics market is expected to expand at 42% CAGR over the next three years. Globally the market is expected to grow from $13B in 2019 to $28.5B by 2026.
  • MedGenome claims its has already built the largest database of South Asian genetic variants through its leadership in genetic diagnostics in India, has completed over 200,000 genomic tests to date and obtains samples from more than 550 hospitals and 6000 clinicians across India.
  • MedGenome provides doctor-prescribed genetic diagnostic tests for patients done by clinicians. Apart from this, the team also believes that the data regarding the Indian population is a great source of genomics research. This allows them to understand the history and pattern of a disease, which gives enough data for research. The MedGenome lab today offers a string of end-to-end diagnostics solutions.
  • “India suffers the largest burden of inherited diseases with about 5-6 percent of the children born affected. Further, the adoption of Western lifestyles has largely increased the occurrence of diabetes, cancer, and cardiovascular diseases, we are creating the road for genetic testing in India. There aren’t many people who have stepped into the space. The market is huge and big enough to support a large number of players. In fact, more people are needed to develop the market,” says Santhosh.

References

  1. Sindhu Kashyaap, 2017, From software to genomes — MedGenome’s journey in making genomics research mainstream in India, Yourstory
  2. J Vignesh, 2018, Oncology solutions company Mitra Biotech gets $40 million, The Economics Times
  3. Aditi Shrivastava, 2019, Biopharma Co Vyome gets Rs 154 crore from investors, The Economics Times
  4. MANSI KAPUR, 2017, Kavitha Iyer Rodrigues: Molecular formula to success, Fortune India
  5. Ari Altstedter, 2018, At the epicenter of a war, Indian antibiotic startups are fighting back, The Times of India

(Author of the article Anjali Gajra is currently pursuing Pharmaceutical Management degree in Narsee Monjee Institute of Management Studies, Mumbai. The views expressed in the article are solely those of the author in his private capacity)

Tags: Biotechnology
Previous Post

Moderna and Aldevron Announce Expanded Partnership for mRNA Vaccine and Therapeutic Pipeline

Next Post

Bal Pharma launches Favipiravir formulation into Indian market

PRN

PRN

Related Posts

environment start up
Articles

Startups Making Environment More Sustainable

by PRN
June 5, 2021
PharmEasy
Articles

PharmEasy – the online pharmacy start-up

by PRN
June 2, 2021
Mind Over Medicine
Articles

Mind Over Medicine

by PRN
May 29, 2021
Sharvil Patel - Driving the next growth phase of Zydus
Articles

Sharvil Patel – Driving the next growth phase of Zydus

by PRN
May 22, 2021
Mental Health
Articles

Mental Health

by PRN
May 18, 2021
Next Post
Bal Pharma launches Favipiravir formulation into Indian market

Bal Pharma launches Favipiravir formulation into Indian market

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Recent News

Zydus to launch Oxemia

Zydus to launch Oxemia (Desidustat) a treatment for Anemia in patients with Chronic Kidney Disease (CKD)

March 7, 2022
FDA Urges Companies to be 'Recall Ready’ to Protect Public Health as Part of Final Guidance for Voluntary Recalls

US FDA Urges Companies to be ’Recall Ready’ to Protect Public Health

March 6, 2022
FDA Clinical Trial Guidances for Advancing Development of Cancer Treatments

FDA publishes Clinical Trial Guidances for Advancing Development of Cancer Treatments

March 5, 2022
Initiation of Voluntary Recalls Under 21 CFR Part 7, Subpart C

US FDA publishes guidance on Initiation of Voluntary Recalls

March 5, 2022
Kilitch Drugs Commences Rs. 100 Crore New Facility Expansion Plan

Kilitch Drugs Commences Rs. 100 Crore New Facility Expansion Plan

March 5, 2022

Browse by Category

  • Articles
  • Company Focus
  • EDQM
  • EMA
  • European Commision
  • Global Pharma News
  • Guideline News
  • Health Canada
  • Indian Pharma News
  • Interview
  • Medsafe
  • MHRA
  • SAHPRA
  • US FDA
  • Webinar

Browse by Tags

Abbott Alembic alkem Amgen Amneal AstraZeneca bayer biocon Biogen BioNTech Bristol Myers Squibb cipla covid Daiichi Sankyo drreddy Eli Lilly fda Gilead glenmark gsk Incyte Janssen Jubilant lupin MHRA Moderna Natco Novartis Novavax novo nordisk oncology Panacea Biotech Pfizer pharmacy Pharma News Pharmareg News Remdesivir roche sanofi Sun pharma Teva usfda Vaccine Viatris zydus

Contact us

Address:Pharma Reg News, First floor, Shop no.1 , Plot no 241,242, Near Fire station, GIDC, Ankleshwar, Gujarat - 393002.
Phone:+91 8511586232, +91 9029066605
Email:author@pharmaregnews.com

Browse by Tag

Abbott Alembic alkem Amgen Amneal AstraZeneca bayer biocon Biogen BioNTech Bristol Myers Squibb cipla covid Daiichi Sankyo drreddy Eli Lilly fda Gilead glenmark gsk Incyte Janssen Jubilant lupin MHRA Moderna Natco Novartis Novavax novo nordisk oncology Panacea Biotech Pfizer pharmacy Pharma News Pharmareg News Remdesivir roche sanofi Sun pharma Teva usfda Vaccine Viatris zydus

Advertise with us

© 2021 - Pharmaregnews.com. Developed by YESWEUS.

No Result
View All Result
  • Home
  • Indian Pharma News
  • Global Pharma News
  • Guideline News
    • EMA
    • MHRA
    • TGA
    • US FDA
  • Articles
  • Interview
  • Company Focus
  • Pharma Jobs
    • Quality
    • Regulatory Affairs
    • Production
    • Sales and Marketing
    • bioanalytical
    • Clinical
  • Webinar
  • Contact us
  • Advertise with us
  • Login

© 2021 - Pharmaregnews.com. Developed by YESWEUS.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?